Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study

A. Zeleniuch-Jacquotte; A. Akhmedkhanov; I. Kato; K. L. Koenig; R. E. Shore; M. Y. Kim; M. Levitz; K. R. Mittal; U. Raju; S. Banerjee; P. Toniolo

doi:10.1054/bjoc.2001.1704

Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study

A. Zeleniuch-Jacquotte, A. Akhmedkhanov, I. Kato, K. L. Koenig, R. E. Shore, M. Y. Kim, M. Levitz, K. R. Mittal, U. Raju, S. Banerjee, P. Toniolo

Research output: Contribution to journal › Article › peer-review

131 Scopus citations

Abstract

We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case-control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P < 0.001), and oestrone (OR = 3.9, P < 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels.

Original language	English (US)
Pages (from-to)	975-981
Number of pages	7
Journal	British Journal of Cancer
Volume	84
Issue number	7
DOIs	https://doi.org/10.1054/bjoc.2001.1704
State	Published - Apr 6 2001
Externally published	Yes

Keywords

Body mass index
Endometrial cancer
Nested case-control study
Oestradiol
Oestrogen
SHBG

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1054/bjoc.2001.1704

Cite this

@article{f40d5724951046448b0b3f6faee9f1db,

title = "Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study",

abstract = "We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case-control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P < 0.001), and oestrone (OR = 3.9, P < 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels.",

keywords = "Body mass index, Endometrial cancer, Nested case-control study, Oestradiol, Oestrogen, SHBG",

author = "A. Zeleniuch-Jacquotte and A. Akhmedkhanov and I. Kato and Koenig, {K. L.} and Shore, {R. E.} and Kim, {M. Y.} and M. Levitz and Mittal, {K. R.} and U. Raju and S. Banerjee and P. Toniolo",

note = "Funding Information: Supported by grants CA66189, CA34588, and CA16087 from the National Cancer Institute, National Institutes of Health. We thank Dr Louise A Brinton for providing a copy of the questionnaire used in a multi-centre case–control study of endometrial cancer that we used as a model in the development of our own questionnaire, Dr Susan Hankinson for the unpublished data used in our analysis correcting for error in measurement, and Dr Walter C Willett for providing the Nurses{\textquoteright} Health Study oral contraceptives booklets. We also thank Samantha Garbers for her help in developing the hormone replacement therapy booklet. We thank Nicole Heitler and Joyce Hansen who conducted all the telephone interviews, and Jo-Ann Cutrone, Daniela Masciangelo, and Lynne Quinones for technical assistance.",

year = "2001",

month = apr,

day = "6",

doi = "10.1054/bjoc.2001.1704",

language = "English (US)",

volume = "84",

pages = "975--981",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Postmenopausal endogenous oestrogens and risk of endometrial cancer

T2 - Results of a prospective study

AU - Zeleniuch-Jacquotte, A.

AU - Akhmedkhanov, A.

AU - Kato, I.

AU - Koenig, K. L.

AU - Shore, R. E.

AU - Kim, M. Y.

AU - Levitz, M.

AU - Mittal, K. R.

AU - Raju, U.

AU - Banerjee, S.

AU - Toniolo, P.

N1 - Funding Information: Supported by grants CA66189, CA34588, and CA16087 from the National Cancer Institute, National Institutes of Health. We thank Dr Louise A Brinton for providing a copy of the questionnaire used in a multi-centre case–control study of endometrial cancer that we used as a model in the development of our own questionnaire, Dr Susan Hankinson for the unpublished data used in our analysis correcting for error in measurement, and Dr Walter C Willett for providing the Nurses’ Health Study oral contraceptives booklets. We also thank Samantha Garbers for her help in developing the hormone replacement therapy booklet. We thank Nicole Heitler and Joyce Hansen who conducted all the telephone interviews, and Jo-Ann Cutrone, Daniela Masciangelo, and Lynne Quinones for technical assistance.

PY - 2001/4/6

Y1 - 2001/4/6

N2 - We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case-control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P < 0.001), and oestrone (OR = 3.9, P < 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels.

AB - We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case-control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P < 0.001), and oestrone (OR = 3.9, P < 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels.

KW - Body mass index

KW - Endometrial cancer

KW - Nested case-control study

KW - Oestradiol

KW - Oestrogen

KW - SHBG

UR - http://www.scopus.com/inward/record.url?scp=17744376755&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17744376755&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2001.1704

DO - 10.1054/bjoc.2001.1704

M3 - Article

C2 - 11286480

AN - SCOPUS:17744376755

SN - 0007-0920

VL - 84

SP - 975

EP - 981

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 7

ER -

Postmenopausal endogenous oestrogens and risk of endometrial cancer: Results of a prospective study

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this